`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`ALLERGAN, INC.
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01130
`Patent 8,633,162
`
`
`
`
`
`
`
`
`
`
`PATENT OWNER ALLERGAN, INC.’S MOTION TO SEAL
`UNDER 37 CFR §§ 42.14 and 42.55
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`Pursuant to 35 U.S.C. § 316 and 37 C.F.R. §§ 42.14 and 42.55, Allergan,
`
`Inc. (“Patent Owner”) respectfully submit this Motion to Seal Exhibits ALL 2028,
`
`ALL 2038, ALL 2046, ALL 2051, ALL 2055, ALL 2056, ALL 2057, ALL 2061,
`
`ALL 2062, ALL 2063, ALL 2054, ALL 2065, ALL 2072, and ALL 2073, which
`
`are being filed concurrent with the Response to Petition and this Motion, such that
`
`they are available to the Board and Parties only.
`
`In support of this Motion, Patent Owner states as follows:
`
`1.
`
`Exhibit ALL 2038 is a true and correct copy of the deposition
`
`transcript of David LeCause, Petitioner’s Vice President of U.S. Eye
`
`Care Sales, taken on February 10, 2017 in Civil Action No. 2:15-cv-
`
`1455-WCB (E.D. Tex.). The deposition transcript contains
`
`confidential information regarding financials, sales, and marketing of
`
`Petitioner’s Restasis® product.
`
`2.
`
`Exhibits ALL 2046 and ALL 2063 are true and correct copies of
`
`confidential strategic marketing plans for Petitioner’s Restasis®
`
`product. The strategic plans contain confidential financial,
`
`marketing, and forecast information regarding Restasis®.
`
`3.
`
`Exhibit ALL 2051 is a true and correct copy of a confidential U.S.
`
`Profit & Loss statement for Petitioner’s Restasis® product. The Profit
`
`& Loss statement contains confidential information regarding
`
`1
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`Petitioner’s revenues, expenses, and profits related to Restasis®.
`
`4.
`
`Exhibits ALL 2055, ALL 2056, and ALL 2057 are true and correct
`
`copies of confidential documents detailing managed care coverage for
`
`Petitioner’s Restasis® product. These documents contain confidential
`
`information regarding formulary coverage and reimbursement for
`
`Restasis® from managed care organizations.
`
`5.
`
`Exhibits ALL 2061, ALL 2062, ALL 2064, and ALL 2065 are true
`
`and correct copies of confidential marketing plans related to
`
`Petitioner’s Restasis® product. These documents contain confidential
`
`information regarding sales, marketing, and financial information
`
`regarding Restasis®.
`
`6.
`
`Exhibit ALL 2072 is a true and correct copy of a document detailing
`
`internal prescription data for Petitioner’s Restasis® product. The
`
`document contains confidential internal information regarding
`
`Restasis® prescriptions.
`
`7.
`
`Exhibit ALL 2073 is a true and correct copy of a document detailing
`
`research and development expenses Petitioner incurred in developing
`
`Restasis®. The document contains confidential information regarding
`
`Petitioner’s development expenses.
`
`2
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`Exhibit ALL 2028 is a true and correct copy of a Declaration by
`
`8.
`
`Robert S. Maness, Ph.D. The document is confidential as it discusses
`
`one or more of the exhibits denoted as confidential.
`
`9.
`
`The information included in Exhibits ALL 2028, ALL 2038, ALL
`
`2046, ALL 2051, ALL 2055, ALL 2056, ALL 2057, ALL 2061, ALL
`
`2062, ALL 2063, ALL 2054, ALL 2065, ALL 2072, and ALL 2073 is
`
`of a truly sensitive nature, and is being offered for the sole purpose of
`
`assisting the Board with understanding Patent Owner’s arguments
`
`regarding non-obviousness.
`
`For these reasons, Patent Owner respectfully requests the Board grant this
`
`Motion to Seal.
`
`Pursuant to 37 CFR § 42.55(a), Patent Owner proposes entry of the default
`
`protective order found in Appendix B of the Trial Practice Guide.
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`/Dorothy P. Whelan /
`Dorothy P. Whelan, Reg. No. 33,814
`Michael J. Kane, Reg. No. 39,722
`Attorneys for Allergan, Inc.
`
`
`
`3
`
`
`
`
`
`Date: /March 20, 2017/
`
`
`
`Customer Number 26191
`Fish & Richardson P.C.
`Telephone: (612) 337-2509
`Facsimile: (612) 288-9696
`
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`DEFAULT PROTECTIVE ORDER
`
`The following Standing Protective Order will be automatically entered into the
`
`proceeding upon the filing of a petition for review or institution of a derivation:
`
`Standing Protective Order
`
`This standing protective order governs the treatment and filing of confidential
`
`information, including documents and testimony.
`
`1. Confidential information shall be clearly marked “PROTECTIVE ORDER
`
`MATERIAL.”
`
`2. Access to confidential information is limited to the following individuals
`
`who have executed the acknowledgment appended to this order:
`
`(A) Parties. Persons who are owners of a patent involved in the
`
`proceeding and other persons who are named parties to the
`
`proceeding.
`
`(B) Party Representatives. Representatives of record for a party in the
`
`proceeding.
`
`(C) Experts. Retained experts of a party in the proceeding who further
`
`certify in the Acknowledgement that they are not a competitor to any
`
`party, or a consultant for, or employed by, such a competitor with
`
`respect to the subject matter of the proceeding.
`
`(D) In-house counsel. In-house counsel of a party.
`
`4
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`(E) Other Employees of a Party. Employees, consultants or other persons
`
`performing work for a party, other than in-house counsel and in-house
`
`counsel’s support staff, who sign the Acknowledgement shall be
`
`extended access to confidential information only upon agreement of
`
`the parties or by order of the Board upon a motion brought by the
`
`party seeking to disclose confidential information to that person. The
`
`party opposing disclosure to that person shall have the burden of
`
`proving that such person should be restricted from access to
`
`confidential information.
`
`(F) The Office. Employees and representatives of the Office who have a
`
`need for access to the confidential information shall have such access
`
`without the requirement to sign an Acknowledgement. Such
`
`employees and representatives shall include the Director, members of
`
`the Board and their clerical staff, other support personnel, court
`
`reporters, and other persons acting on behalf of the Office.
`
`(G) Support Personnel. Administrative assistants, clerical staff, court
`
`reporters and other support personnel of the foregoing persons who
`
`are reasonably necessary to assist those persons in the proceeding
`
`shall not be required to sign an Acknowledgement, but shall be
`
`5
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`informed of the terms and requirements of the Protective Order by the
`
`person they are supporting who receives confidential information.
`
`3. Persons receiving confidential information shall use reasonable efforts to
`
`maintain the confidentiality of the information, including:
`
`(A) Maintaining such information in a secure location to which persons
`
`not authorized to receive the information shall not have access;
`
`(B) Otherwise using reasonable efforts to maintain the confidentiality of
`
`the information, which efforts shall be no less rigorous than those the
`
`recipient uses to maintain the confidentiality of information not
`
`received from the disclosing party;
`
`(C) Ensuring that support personnel of the recipient who have access to
`
`the confidential information understand and abide by the obligation to
`
`maintain the confidentiality of information received that is designated
`
`as confidential; and
`
`(D) Limiting the copying of confidential information to a reasonable
`
`number of copies needed for conduct of the proceeding and
`
`maintaining a record of the locations of such copies.
`
`4. Persons receiving confidential information shall use the following
`
`procedures to maintain the confidentiality of the information:
`
`(A) Documents and Information Filed With the Board.
`
`6
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`(i) A party may file documents or information with the Board
`
`under seal, together with a non-confidential description of
`
`the nature of the confidential information that is under seal
`
`and the reasons why the information is confidential and
`
`should not be made available to the public. The submission
`
`shall be treated as confidential and remain under seal,
`
`unless, upon motion of a party and after a hearing on the
`
`issue, or sua sponte, the Board determines that the
`
`documents or information do not to qualify for confidential
`
`treatment.
`
`(ii)
`
` Where confidentiality is alleged as to some but not all of
`
`the information submitted to the Board, the submitting
`
`party shall file confidential and non-confidential versions
`
`of its submission, together with a Motion to Seal the
`
`confidential version setting forth the reasons why the
`
`information redacted from the non-confidential version is
`
`confidential and should not be made available to the
`
`public. The non-confidential version of the submission
`
`shall clearly indicate the locations of information that has
`
`been redacted. The confidential version of the submission
`
`7
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`shall be filed under seal. The redacted information shall
`
`remain under seal unless, upon motion of a party and after
`
`a hearing on the issue, or sua sponte, the Board determines
`
`that some or all of the redacted information does not
`
`qualify for confidential treatment.
`
`(B) Documents and Information Exchanged Among the Parties.
`
`Information designated as confidential that is disclosed to another
`
`party during discovery or other proceedings before the Board shall be
`
`clearly marked as “PROTECTIVE ORDER MATERIAL” and shall
`
`be produced in a manner that maintains its confidentiality.
`
`5. (j) Standard Acknowledgement of Protective Order. The following form
`
`may be used to acknowledge a protective order and gain access to
`
`information covered by the protective order:
`
`
`
`8
`
`
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`ALLERGAN, INC.
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-01130
`Patent 8,633,162
`
`
`
`
`
`
`
`
`
`
`Standard Acknowledgment for Access to Protective Order Material
`
`
`
`I __________________________________________, affirm that I have read the
`
`Protective Order; that I will abide by its terms; that I will use the confidential
`
`information only in connection with this proceeding and for no other purpose; that
`
`I will only allow access to support staff who are reasonably necessary to assist me
`
`9
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`in this proceeding; that prior to any disclosure to such support staff I informed or
`
`will inform them of the requirements of the Protective Order; that I am personally
`
`responsible for the requirements of the terms of the Protective Order and I agree to
`
`submit to the jurisdiction of the Office and the United States District Court for the
`
`Eastern District of Virginia for purposes of enforcing the terms of the Protective
`
`Order and providing remedies for its breach.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By
`
`Date:
`
`10
`
`
`
`
`
`Case IPR2016-01130
`Attorney Docket No: 13351-0008IP4
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR §§ 42.6(e)(4) and 42.205(b), the undersigned certifies
`
`that on March 20, 2017, a complete and entire copy of this Patent Owner Allergan,
`
`Inc.’s Motion to Seal was provided via electronic service, to the Petitioner by
`
`serving the correspondence address of record as follows:
`
`Steven W. Parmelee
`Michael T. Rosato
`Jad A. Mills
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` /Jessica K. Detko/
`
`Jessica K. Detko
`Fish & Richardson P.C.
`60 South Sixth Street, Suite 3200
`Minneapolis, MN 55402
`(612) 337-2516
`
`
`
`
`
`
`
`
`
`
`11
`
`